The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Neuropsychological performance and urinary phenylethylamine in Tourette's syndrome

Published Online:https://doi.org/10.1176/jnp.3.4.417

Patients with Tourette's syndrome (TS) were grouped on the basis of levels of urinary phenylethylamine (PEA). These groups of TS patients were compared on an extensive battery of neuropsychological measures converted to age-corrected T scores based on published normative data. Patients with PEA levels below that of normal controls performed significantly worse than TS patients with normal PEA levels. The data were interpreted to suggest that abnormalities in PEA may contribute to neuropsychological deficits. Furthermore, these data may provide further support for an etiological subgroup of TS patients characterized by an abnormality in PEA metabolism. These data are discussed in regard to directions for further investigation.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.